MA59447B1 - Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer - Google Patents

Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer

Info

Publication number
MA59447B1
MA59447B1 MA59447A MA59447A MA59447B1 MA 59447 B1 MA59447 B1 MA 59447B1 MA 59447 A MA59447 A MA 59447A MA 59447 A MA59447 A MA 59447A MA 59447 B1 MA59447 B1 MA 59447B1
Authority
MA
Morocco
Prior art keywords
ylmethanol
azetidine
derivatives
cancer treatment
receptor modulators
Prior art date
Application number
MA59447A
Other languages
English (en)
Inventor
Francis Hubler
Eva Caroff
Emmanuel Meyer
Sylvia Richard-Bildstein
Oliver Allemann
Alexia CHAVANTON-ARPEL
Andrew CROXFORD
Loïc JACOB
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA59447B1 publication Critical patent/MA59447B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (I), leur synthèse et leur utilisation en tant que modulateurs du récepteur CCR6 pour le traitement ou la prévention de diverses maladies, affections ou divers troubles.
MA59447A 2020-04-30 2021-04-30 Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer MA59447B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2020062103 2020-04-30
PCT/EP2021/061401 WO2021219849A1 (fr) 2020-04-30 2021-04-30 Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6
EP21722227.2A EP4143179B1 (fr) 2020-04-30 2021-04-30 Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA59447B1 true MA59447B1 (fr) 2025-12-31

Family

ID=75728860

Family Applications (1)

Application Number Title Priority Date Filing Date
MA59447A MA59447B1 (fr) 2020-04-30 2021-04-30 Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer

Country Status (19)

Country Link
US (1) US12617773B2 (fr)
EP (1) EP4143179B1 (fr)
JP (1) JP7789693B2 (fr)
KR (1) KR20230005938A (fr)
CN (1) CN115551841A (fr)
AR (1) AR121982A1 (fr)
AU (1) AU2021266148A1 (fr)
BR (1) BR112022021976A2 (fr)
CA (1) CA3177335A1 (fr)
ES (1) ES3055903T3 (fr)
HR (1) HRP20251578T1 (fr)
IL (1) IL297675B1 (fr)
MA (1) MA59447B1 (fr)
PH (1) PH12022500015A1 (fr)
PL (1) PL4143179T3 (fr)
RS (1) RS67648B1 (fr)
TW (1) TWI904157B (fr)
UA (1) UA130467C2 (fr)
WO (1) WO2021219849A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
WO2023072924A1 (fr) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
AU2022374959A1 (en) 2021-10-28 2024-06-06 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
CN120457123A (zh) 2022-12-06 2025-08-08 爱杜西亚药品有限公司 Ccr6拮抗剂的结晶己二酸盐形式

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28141A (en) 1860-05-08 Stephen l
US3458635A (en) 1966-08-08 1969-07-29 Robins Co Inc A H Compositions containing 3-di-substituted methylene pyrrolidines and methods of treating depression
US3479370A (en) 1966-08-08 1969-11-18 Robins Co Inc A H Esters of 1-substituted-3-disubstituted-pyrrolidinemethanols
US3499002A (en) 1968-06-20 1970-03-03 Robins Co Inc A H 1-carbamoyl-3-aroylpyrrolidines
US3489769A (en) 1968-06-20 1970-01-13 Robins Co Inc A H 1-substituted-3-aroyl-pyrrolidines
US3651085A (en) 1969-04-14 1972-03-21 Robins Co Inc A H 1-(omega-benzoylalkyl)-3-substituted pyrrolidines
US3542807A (en) 1969-04-14 1970-11-24 Robins Co Inc A H 1-(omega-benzoylalkyl)-3-substituted pyrrolidines
US3694458A (en) 1970-08-31 1972-09-26 Robins Co Inc A H 1-nitrosopyrrolidines
US5278045A (en) 1990-02-28 1994-01-11 Du Pont Merck Pharmaceutical Company Method and compositions to screen compounds for enhancement of the cholinergic, dopaminergic and serotonergic function
CA2132848A1 (fr) 1992-03-27 1993-10-14 Richard Friary Derives bis-arylcarbinol non pontes, compositions de ceux-ci et methodes d'utilisation
FR2775477B1 (fr) 1998-02-27 2000-05-19 Union Pharma Scient Appl Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique
DE10144872A1 (de) * 2001-09-12 2003-03-27 Bayer Cropscience Gmbh Azetidinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
UY29610A1 (es) 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
WO2007022351A2 (fr) 2005-08-18 2007-02-22 Glaxo Group Limited Antagonistes de recepteurs d'acetylcholine muscarinique
CA2675942C (fr) 2007-02-23 2016-04-12 Theravance, Inc. Composes de diphenylmethyle d'ammonium quartenaire utilises comme antagonistes de recepteur muscarinique
WO2010131146A1 (fr) 2009-05-12 2010-11-18 Pfizer Limited Dérivés de cyclobutène-dione
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CN103588697B (zh) 2012-08-14 2017-09-15 中国科学院上海药物研究所 一类2，5‑二取代苯磺酰胺类化合物及其制备方法和用途
JP6466335B2 (ja) 2012-10-16 2019-02-06 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−γ−Ｔのメチレン連結キノリニルモジュレーター
CN103800309A (zh) 2012-11-15 2014-05-21 中国科学院上海药物研究所 金精三羧酸在制备靶向趋化因子受体的药物中的用途
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
JP6346275B2 (ja) * 2013-10-15 2018-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−γ−Ｔのメチレン結合キノリニルモジュレーター
EA029826B1 (ru) 2013-12-02 2018-05-31 Кемосентрикс, Инк. Соединения против ccr6
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
AU2018318075B2 (en) 2017-08-14 2023-04-13 Allergan, Inc. 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
WO2019105915A1 (fr) 2017-11-28 2019-06-06 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
AU2019212478C1 (en) 2018-01-26 2023-11-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
GEP20237476B (en) * 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
WO2023072924A1 (fr) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
AU2022374959A1 (en) 2021-10-28 2024-06-06 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
CN120457123A (zh) 2022-12-06 2025-08-08 爱杜西亚药品有限公司 Ccr6拮抗剂的结晶己二酸盐形式

Also Published As

Publication number Publication date
PL4143179T3 (pl) 2026-03-23
JP2023523300A (ja) 2023-06-02
EP4143179A1 (fr) 2023-03-08
ES3055903T3 (en) 2026-02-16
HRP20251578T1 (hr) 2026-01-30
EP4143179C0 (fr) 2025-10-22
TW202200560A (zh) 2022-01-01
BR112022021976A2 (pt) 2022-12-13
KR20230005938A (ko) 2023-01-10
EP4143179B1 (fr) 2025-10-22
WO2021219849A1 (fr) 2021-11-04
PH12022500015A1 (en) 2023-09-11
TWI904157B (zh) 2025-11-11
US20230174514A1 (en) 2023-06-08
US12617773B2 (en) 2026-05-05
IL297675B1 (en) 2026-03-01
JP7789693B2 (ja) 2025-12-22
UA130467C2 (uk) 2026-02-25
AU2021266148A1 (en) 2023-01-05
CN115551841A (zh) 2022-12-30
CA3177335A1 (fr) 2021-11-04
AR121982A1 (es) 2022-07-27
IL297675A (en) 2022-12-01
RS67648B1 (sr) 2026-02-27

Similar Documents

Publication Publication Date Title
MA58181B1 (fr) Composés tricycliques substitués
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA33832B1 (fr) Isoquinolinones et quinazolinones substituées
MA51669B1 (fr) Modulateurs de tmem16a
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA33552B1 (fr) Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques
MA54133B1 (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
MA52482B1 (fr) Dérivés de spiropipéridine en tant que modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA50398B1 (fr) Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
PH12022500015A1 (en) Ccr6 receptor modulators
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA49127B1 (fr) Dérivés d'indole n-substitués
MA27629A1 (fr) Dérivés du benzènesulfonamide, leur procédé de préparation et leur utilisation pour le traitement de la douleur.
MA68743B1 (fr) Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa